- Home
- UAN vs KARD Comparison
UAN vs KARD Comparison
Compare UAN & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UAN | KARD |
|---|---|---|
| Founded | 2007 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Agricultural Chemicals | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2008 | 2026 |
Fundamental Metrics
Financial Performance| Metric | UAN | KARD |
|---|---|---|
| Price | $126.75 | $13.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $41.00 |
| AVG Volume (30 Days) | 13.3K | ★ 577.7K |
| Earning Date | 11-03-2026 | 11-22-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | ★ 61.98 | N/A |
| EPS | ★ 12.06 | N/A |
| Revenue | ★ $606,038,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $50.00 |
| P/E Ratio | $10.52 | ★ N/A |
| Revenue Growth | ★ 15.36 | N/A |
| 52 Week Low | $93.43 | $12.23 |
| 52 Week High | $139.50 | $27.00 |
Technical Indicators
Market Signals| Indicator | UAN | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 47.84 | 45.51 |
| Support Level | $122.12 | $13.75 |
| Resistance Level | $139.42 | $15.93 |
| Average True Range (ATR) | 2.98 | 0.99 |
| MACD | 0.03 | 0.30 |
| Stochastic Oscillator | 19.71 | 55.85 |
Price Performance
Historical ComparisonAbout UAN CVR Partners LP
CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.
About KARD Kardigan Inc. Common Stock
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.